Research programme: allergy vaccines - Anergis

Drug Profile

Research programme: allergy vaccines - Anergis

Alternative Names: AllerDM; AllerDM dust mites - Anergis; AllerG; AllerG grass - Anergis; AllerJ; AllerJ Japanese cedar - Anergis; AllerR; AllerR ragweed - Anergis

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Lausanne
  • Developer Anergis
  • Class Allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypersensitivity
  • No development reported Bee venom hypersensitivity; Grass pollen hypersensitivity; Ragweed pollen hypersensitivity; Tree pollen hypersensitivity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bee-venom-hypersensitivity(Prevention) in Switzerland (SC, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Ragweed pollen hypersensitivity(Prevention) in Switzerland (SC, Injection)
  • 16 Jul 2016 No recent reports of development identified for research development in Grass pollen hypersensitivity(Prevention) in Switzerland (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top